GSK plc

GSK

Cena:

$ 51.38

-0.15 (-0.29%)

Valuace

Růst

Zdraví

Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři

Souhrn

Finanční data

Pro investory

Předpovědi

Zprávy

Dividendy

Zisky

Návštěvnost webu

Akcionáři

Zprávy

Zahraniční články

Tiskové zprávy

Dokumenty ke stáhnutí

Here's Why GSK (GSK) is a Strong Value Stock

10:41 22-05-2026

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the ...

GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?

11:26 21-05-2026

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug s...

ASML Holding NV: A Significant Exit in Mark Hillman's Q1 2026 Portfolio Adjustments

7:02 15-05-2026

Exploring the Strategic Moves of a Seasoned Investor Mark Hillman (Trades, Portfolio) recently submi...

GSK to team up with Sino Biopharma for China launch of hepatitis B treatment

2:28 11-05-2026

GSK on Monday ‌said it had entered into ⁠a strategic collaboration with Hong Kong...

Why GSK (GSK) is a Top Value Stock for the Long-Term

10:40 30-04-2026

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi...

GSK plc (GSK) Q1 2026 Earnings Call Transcript

15:01 29-04-2026

GSK plc (GSK) Q1 2026 Earnings Call Transcript...

GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth

11:31 29-04-2026

GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology ...

GSK (GSK) Tops Q1 Earnings and Revenue Estimates

8:10 29-04-2026

GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate ...

UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

5:32 29-04-2026

Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both repo...

GSK reaffirms 2026 guidance after strong first-quarter performance

3:04 29-04-2026

GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 g...

GSK Earnings Boosted by Higher Specialty Medicine Sales

2:45 29-04-2026

The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compare...

GSK beats quarterly profit estimates on strength in respiratory, general medicines

2:06 29-04-2026

British drugmaker GSK reported first-quarter ‌profit above analysts' expectations on Wednesd...

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

2:06 28-04-2026

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today anno...

GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio

3:01 27-04-2026

GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after ...

GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of “Reduce” by Brokerages

2:38 27-04-2026

Shares of GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) have been assigned a consensus recomme...

GSK (GSK) Earnings Expected to Grow: Should You Buy?

11:02 22-04-2026

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings b...

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

9:15 20-04-2026

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management ...

GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential

7:42 19-04-2026

GSK maintains a 'Strong Buy' rating, driven by robust Oncology portfolio growth and promising pipeli...

GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest

3:19 16-04-2026

GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) saw a significant increase in short interest in ...

GSK sees blockbuster potential in targeted cancer therapy after promising early data

10:12 12-04-2026

British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head...

RAPT THERAPEUTICS INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF RAPT THERAPEUTICS, INC. - RAPT

05-02-2026

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ...

Více zde

RAPT THERAPEUTICS INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF RAPT THERAPEUTICS, INC. - RAPT

21-01-2026

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ...

Více zde

GSK AWARDS $2M IN COIMMUNITY INITIATIVE GRANTS TO HELP CLOSE VACCINATION GAPS, COMMITS $3M FOR 2026

21-01-2026

PHILADELPHIA--(BUSINESS WIRE)-- #DISEASEEDUCATION--GSK AWARDS $2M IN COIMMUNITY INITIATIVE GRANTS TO...

Více zde

FORBION ANNOUNCES SECOND EXIT FROM FORBION GROWTH FUND III FOLLOWING $2.2 BILLION ACQUISITION OF RAPT THERAPEUTICS BY GSK

20-01-2026

NAARDEN, THE NETHERLANDS, JAN. 20, 2026 (GLOBE NEWSWIRE) -- FORBION, A LEADING LIFE SCIENCES VENTURE...

Více zde

GSK ANNOUNCES RECIPIENTS OF LINKED BY LUPUS: OPTIMAL CARE INITIATIVE GRANTS NEARING $1 MILLION

20-01-2026

PHILADELPHIA--(BUSINESS WIRE)--GSK PLC (LSE/NYSE: GSK) HAS ANNOUNCED THE RECIPIENTS OF THE LINKED BY...

Více zde

ALTEOGEN ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH TESARO, A SUBSIDIARY OF GSK, FOR THE DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF DOSTARLIMAB ENABLED BY HYBROZYME™ TECHNOLOGY

20-01-2026

DAEJEON, SOUTH KOREA, JAN. 20, 2026 /PRNEWSWIRE/ -- ALTEOGEN INC. (KOSDAQ: 196170) ANNOUNCED TODAY ...

Více zde

SUMMIT THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH GSK TO EVALUATE IVONESCIMAB IN COMBINATION WITH GSK'S B7-H3 ANTIBODY DRUG CONJUGATE (ADC)

12-01-2026

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) TODAY ANNOUNCED IT HAS ENT...

Více zde

ANAPTYS FILES MOTION TO DISMISS TESARO'S CLAIM OF ANTICIPATORY BREACH OF CONTRACT IN ONGOING LITIGATION AGAINST TESARO, A GSK SUBSIDIARY

08-01-2026

SAN DIEGO, JAN. 08, 2026 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTE...

Více zde

GSK LICENSES NOETIK'S AI FOUNDATION MODELS IN ANCHOR PARTNERSHIP TO TRANSFORM CANCER THERAPEUTIC RESEARCH AND DEVELOPMENT

08-01-2026

SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK LICENSES NOETIK'S AI FOUNDATION MODELS IN ANCHOR PARTNERS...

Více zde

IONIS PARTNER GSK ANNOUNCES POSITIVE TOPLINE RESULTS FROM B-WELL 1 AND B-WELL 2 PHASE 3 STUDIES FOR BEPIROVIRSEN, A POTENTIAL FIRST-IN-CLASS MEDICINE FOR CHRONIC HEPATITIS B

07-01-2026

CARLSBAD, CALIF.--(BUSINESS WIRE)--IONIS PHARMACEUTICALS, INC. (NASDAQ: IONS) PARTNER GSK TODAY ANNO...

Více zde

SAMSUNG BIOLOGICS EXPANDS U.S. MANUFACTURING CAPABILITIES WITH STRATEGIC ACQUISITION OF HUMAN GENOME SCIENCES FROM GSK

21-12-2025

SECURES THE COMPANY'S FIRST U.S.-BASED MANUFACTURING SITE, STRENGTHENING AND DIVERSIFYING ITS GLOBAL...

Více zde

SPERO ANNOUNCES NDA RESUBMISSION OF TEBIPENEM HBR BY GSK TO THE FDA FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS

19-12-2025

CAMBRIDGE, MASS., DEC. 19, 2025 (GLOBE NEWSWIRE) -- SPERO THERAPEUTICS, INC. (NASDAQ: SPRO), A CLIN...

Více zde

EXDENSUR (DEPEMOKIMAB) APPROVED BY US FDA FOR THE TREATMENT OF SEVERE ASTHMA

16-12-2025

PHILADELPHIA--(BUSINESS WIRE)--GSK PLC (LSE/NYSE: GSK) TODAY ANNOUNCED THAT THE US FOOD AND DRUG ADM...

Více zde

OXFORD BIOTHERAPEUTICS ENTERS INTO A STRATEGIC COLLABORATION WITH GSK TO DISCOVER NOVEL TARGETS FOR ANTIBODY-BASED THERAPEUTICS FOR THE TREATMENT OF CANCER

10-12-2025

OXFORD, UK AND SAN JOSE, CALIFORNIA , 10TH DECEMBER 2025 – OXFORD BIOTHERAPEUTICS (OBT), A CLINICA...

Více zde

ANAPTYS INITIATES LITIGATION AGAINST TESARO, A GSK SUBSIDIARY

21-11-2025

SAN DIEGO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTE...

Více zde

AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)

10-11-2025

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMP...

Více zde

ANAPTYS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

04-11-2025

ANNOUNCED INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YE 2026 PHASE 2...

Více zde

BLENREP APPROVED BY US FDA FOR USE IN TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

23-10-2025

PHILADELPHIA--(BUSINESS WIRE)-- #BELANTAMABMAFODOTIN--BLENREP APPROVED BY US FDA FOR USE IN TREATMEN...

Více zde

NEW LOCAL DATA IN GSK AND IQVIA'S VACCINE TRACK SUPPORTS SMARTER PUBLIC HEALTH ACTION AT THE COMMUNITY LEVEL

01-10-2025

PHILADELPHIA--(BUSINESS WIRE)-- #ADULTVACCINATION--GSK PLC (LSE/NYSE: GSK) TODAY ANNOUNCED A MAJOR U...

Více zde

PI HEALTH TO COLLABORATE WITH GSK TO ENHANCE CLINICAL RESEARCH SERVICES

24-09-2025

CAMBRIDGE, MASS.--(BUSINESS WIRE)--PI HEALTH, A GLOBAL HEALTH TECHNOLOGY AND CLINICAL RESEARCH COMPA...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC - GSK

03-09-2025

NEW YORK , SEPT. 3, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

02-09-2025

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVE...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

29-08-2025

NEW YORK, AUG. 29, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC - GSK

22-08-2025

NEW YORK , AUG. 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

21-08-2025

NEW YORK, AUG. 21, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

17-08-2025

NEW YORK, AUG. 17, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC - GSK

16-08-2025

NEW YORK , AUG. 16, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

13-08-2025

NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC - GSK

11-08-2025

NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...

Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF GSK PLC – GSK

09-08-2025

NEW YORK, AUG. 09, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...

Více zde

Dokumenty nejsou k dispozici